Skip to main content
Article
Sitagliptin Therapy in Kidney Transplant Recipients With New-Onset Diabetes After Transplantation
Transplantation
  • James T. Lane
  • David E. Odegaard
  • Claire E. Haire
  • Dean S. Collier
  • Lucile E. Wrenshall, Wright State University - Main Campus
  • R. Brian Stevens, Wright State University
Document Type
Article
Publication Date
11-27-2011
Abstract

New-onset diabetes after transplantation (NODAT) remains a frequent and serious complication after kidney transplantation. We previously reported NODAT in our postkidney transplant population at a frequency of more than 50%, using the definition established by the 2003 International Guidelines. This high rate of posttransplant diabetes has serious negative consequences for future cardiovascular risk and survival after kidney transplant.

DOI
10.1097/TP.0b013e3182347ea4
Citation Information
James T. Lane, David E. Odegaard, Claire E. Haire, Dean S. Collier, et al.. "Sitagliptin Therapy in Kidney Transplant Recipients With New-Onset Diabetes After Transplantation" Transplantation Vol. 92 Iss. 10 (2011) p. e56 - e57 ISSN: 00411337
Available at: http://works.bepress.com/r_stevens/35/